FOLFOX 化疗在转移性肠胰神经内分泌肿瘤中的疗效。

Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors.

机构信息

Department of Medical Oncology, ENETS Center of Excellence, IPC NET Center, Institut Paoli-Calmettes, Marseille, France;

Department of Clinical Research and Investigation, Biostatistics and Methodology Unit, Institut Paoli-Calmettes, Aix Marseille University, INSERM, IRD, SESSTIM, Marseille, France.

出版信息

Anticancer Res. 2021 Apr;41(4):2071-2078. doi: 10.21873/anticanres.14977.

DOI:10.21873/anticanres.14977

PMID:33813416

Abstract

BACKGROUND/AIM: FOLFOX (5-Fluorouracile and oxaliplatin) exhibits promising activity in advanced well-differentiated neuroendocrine tumors (NETs). This retrospective study aimed to analyze the outcome of metastatic enteropancreatic NETs patients treated with FOLFOX.

PATIENTS AND METHODS

We retrospectively identified patients treated with FOLFOX for NETs of enteropancreatic or unknown origin among those referred to our Regional Multidisciplinary Tumor Board.

RESULTS

Among 48 patients, most often pancreatic NETs (n=33, 68.8%), the median Ki67 index was 10%. The median number cycle of FOLFOX was 6 and median follow-up was 34.8 months. Disease control rate (DCR) was 83.3%. Median PFS and OS were 12.6 and 29.4 months respectively. Median chemotherapy break was 14.1 months. No significant difference was observed between PFS and the following criteria: Ki67 index, primary tumor site, alkaline phosphatase levels, primary tumor surgery and F-FDG PET positivity.

CONCLUSION

FOLFOX exhibits a high DCR and a short duration of treatment with a relative long chemotherapy break in patients with metastatic enteropancreatic NETs.

摘要

背景/目的：FOLFOX（氟尿嘧啶和奥沙利铂）在晚期分化良好的神经内分泌肿瘤（NETs）中表现出有希望的活性。本回顾性研究旨在分析接受 FOLFOX 治疗的转移性肠胰神经内分泌肿瘤患者的结果。

患者和方法

我们回顾性地确定了在我们的区域多学科肿瘤委员会转诊的患者中，接受 FOLFOX 治疗的肠胰或未知来源的 NETs 患者。

结果

在 48 名患者中，最常见的是胰腺 NETs（n=33，68.8%），Ki67 指数中位数为 10%。FOLFOX 的中位周期数为 6 个，中位随访时间为 34.8 个月。疾病控制率（DCR）为 83.3%。中位无进展生存期（PFS）和总生存期（OS）分别为 12.6 个月和 29.4 个月。中位化疗中断时间为 14.1 个月。PFS 与以下标准之间无显著差异：Ki67 指数、原发肿瘤部位、碱性磷酸酶水平、原发肿瘤手术和 F-FDG PET 阳性。